TY - JOUR
T1 - Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO
AU - Biswas, Swati
AU - Tankhiwale, Neelam
AU - Blackford, Amanda
AU - Barrera, Angelica M.Gutierrez
AU - Ready, Kaylene
AU - Lu, Karen
AU - Amos, Christopher I.
AU - Parmigiani, Giovanni
AU - Arun, Banu
N1 - Funding Information:
Acknowledgments This study was supported in part by the Susan G Komen for the Cure Grant KG081303, an Intramural Seed Grant from the University of North Texas Health Science Center, and the Program in Human and Computational Genomics at MDACC.
PY - 2012/5
Y1 - 2012/5
N2 - The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.
AB - The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.
KW - BRCA1
KW - BRCA2
KW - BRCAPRO
KW - BayesMendel
KW - CancerGene
KW - ER
KW - Genetic risk
KW - Her-2/neu
KW - PR
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=84860324524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860324524&partnerID=8YFLogxK
U2 - 10.1007/s10549-012-1958-z
DO - 10.1007/s10549-012-1958-z
M3 - Article
C2 - 22270937
AN - SCOPUS:84860324524
SN - 0167-6806
VL - 133
SP - 347
EP - 355
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -